Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena 53100, Italy. gennari@unisi.it
Luigi
L
Gennari
John P
JP
Bilezikian
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D010006:Osteoblasts / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D012107:Research Design; D000068296:Risedronic Acid; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid; D000068296:Risedronic Acid; D012968:Etidronic Acid